Is Bliss GVS Pharma overvalued or undervalued?

As of 15 July 2025, Bliss GVS Pharma's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 19.32, an EV to EBITDA of 11.87, and a ROCE of 10.51%.
When compared to peers, Bliss GVS Pharma's valuation stands out against companies like Sun Pharma, which is considered expensive with a PE ratio of 36.25, and Cipla, which is attractive with a PE of 22.85. While Bliss GVS Pharma has shown strong performance over the past year with a return of 33.61% compared to the Sensex's 2.36%, its recent stock performance has been mixed, with a year-to-date decline of 6.19%. Overall, the company appears to be fairly valued in the current market landscape.